Icagen Announces Appointment of Chairman
News Oct 17, 2005
Icagen, Inc. has announced that Charles A. Sanders, M.D., who has served on the Icagen Board of Directors since 1997, has been appointed Chairman of Icagen's Board of Directors.
Dr. Sanders' appointment follows the resignation from Icagen's Board of Directors of H. Jefferson Leighton, Ph.D., who has served as Chairman since 1992.
Dr. Sanders has over forty years of experience in the pharmaceutical industry and academic medicine.
Dr. Sanders served as chairman and chief executive officer of Glaxo Inc. from 1989 to May 1995, and also served as a member of the board of directors of Glaxo plc.
He is currently a member of the Institute of Medicine of the National Academy of Sciences, a member of the CSIS Board of Trustees, chairman of Project HOPE and chairman of the Foundation for the National Institutes of Health.
Dr. Sanders is also past chairman of the New York Academy of Sciences, past chairman of The Commonwealth Fund and past chairman of the Harvard Overseers Committee to Visit the Harvard Medical School.
Jeff Leighton, Ph.D. stated, "After more than twelve years of service on the Icagen Board, I have decided to retire from this position entirely for family reasons."
"It has been a privilege to work with the management team and the Board of Directors at Icagen during this period."
"I continue to believe strongly in the approach of targeting ion channels for the development of novel pharmaceuticals and believe that Icagen is extremely well positioned to continue its research and development efforts in this field."
P. Kay Wagoner, Ph.D., Chief Executive Officer of Icagen, noted, "We thank Jeff for his many years of service on the Icagen Board. Since the Company's inception in 1992, his guidance and counsel have been invaluable."
"Jeff's presence on the Icagen Board will be greatly missed, and we wish him the very best in all his future endeavors. At the same time, we are delighted that Charles Sanders has been appointed our new Chairman."
"His many years of experience in the pharmaceutical industry and medical community will be of great value to the Company as we continue our mission to discover and develop novel pharmaceuticals based upon our core ion channel technology platform."
Dr. Sanders commented, "I thank the Board for this opportunity to serve as Chairman, and look forward to continuing to work with the management team and Board at Icagen as the Company continues to advance its pipeline of clinical and preclinical compounds."
"Speaking for the entire Board, I wish Jeff the very best, and thank him for his many years of dedicated service to the Company."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019